HC Wainwright Issues Pessimistic Outlook for PRAX Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Praxis Precision Medicines in a research note issued on Friday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($3.55) per share for the quarter, down from their prior estimate of ($3.16). HC Wainwright currently has a “Buy” rating and a $1,245.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($15.16) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q3 2026 earnings at ($3.87) EPS, Q4 2026 earnings at ($3.86) EPS, FY2026 earnings at ($14.49) EPS, FY2027 earnings at ($5.33) EPS, FY2028 earnings at $31.73 EPS and FY2029 earnings at $84.46 EPS.

A number of other research firms also recently weighed in on PRAX. Wolfe Research started coverage on Praxis Precision Medicines in a report on Monday, February 23rd. They issued an “outperform” rating and a $500.00 target price on the stock. TD Cowen reissued a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday, January 29th. Robert W. Baird set a $433.00 target price on Praxis Precision Medicines and gave the company an “outperform” rating in a research note on Friday, February 20th. Wells Fargo & Company set a $305.00 target price on Praxis Precision Medicines and gave the company an “equal weight” rating in a research note on Friday, February 20th. Finally, Truist Financial raised Praxis Precision Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Five research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Praxis Precision Medicines has a consensus rating of “Buy” and a consensus price target of $591.83.

Praxis Precision Medicines Price Performance

Praxis Precision Medicines stock opened at $331.81 on Tuesday. Praxis Precision Medicines has a one year low of $35.21 and a one year high of $356.00. The stock has a market capitalization of $9.25 billion, a PE ratio of -24.82 and a beta of 2.76. The business’s fifty day moving average is $317.26 and its 200 day moving average is $279.65.

Praxis Precision Medicines (NASDAQ:PRAX) last released its earnings results on Thursday, May 7th. The company reported ($3.20) EPS for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.38.

Hedge Funds Weigh In On Praxis Precision Medicines

Institutional investors and hedge funds have recently modified their holdings of the stock. Orbis Allan Gray Ltd purchased a new position in Praxis Precision Medicines during the 4th quarter valued at $369,946,000. Janus Henderson Group PLC boosted its holdings in Praxis Precision Medicines by 17.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock valued at $954,834,000 after acquiring an additional 476,227 shares during the period. Barclays PLC boosted its holdings in Praxis Precision Medicines by 592.6% during the 4th quarter. Barclays PLC now owns 530,751 shares of the company’s stock valued at $156,434,000 after acquiring an additional 454,114 shares during the period. Baker BROS. Advisors LP boosted its holdings in Praxis Precision Medicines by 63.4% during the 4th quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock valued at $332,021,000 after acquiring an additional 437,000 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in Praxis Precision Medicines by 27.6% during the 4th quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock valued at $588,297,000 after acquiring an additional 431,432 shares during the period. Hedge funds and other institutional investors own 67.84% of the company’s stock.

More Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Praxis Precision Medicines and reiterated a $1,245 price target, while also nudging up its FY2028 and FY2029 earnings estimates, signaling strong confidence in the company’s long-term potential.
• Positive Sentiment: TipRanks highlighted Praxis Precision Medicines’ “high-stakes launch path” after its Q1 earnings call, suggesting investors are focused on the company’s upcoming commercialization efforts and potential catalyst from its pipeline. Article Title
• Neutral Sentiment: Lifesci Capital lowered its 2026 EPS estimates for PRAX across Q2, Q3, Q4, and full-year 2026, reflecting a more cautious near-term view on earnings, even though the firm did not change the broader story materially.
• Neutral Sentiment: HC Wainwright also trimmed its 2026 and 2027 earnings forecasts, but its long-term estimates remain sharply positive, indicating the revisions are more about timing than a change in the thesis.
• Negative Sentiment: Wedbush reportedly maintained an Underperform rating and flagged concerns about the ulixacaltamide filing, which may be weighing on sentiment by highlighting execution and regulatory risk. Article Title

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.